📊 HOOK Key Takeaways
Is HOOK a Good Investment? Thesis Analysis
HOOKIPA exhibits severe operating losses of $15.4M against minimal $2.0M revenue, indicating unsustainable economics and rapid cash depletion despite strong cash reserves. While 118% revenue growth is encouraging, the company's viability depends entirely on successful pharmaceutical development with unclear path to profitability.
Why Buy HOOK? Key Strengths
- Revenue growth of 118.3% YoY demonstrates market traction and adoption
- Strong liquidity position with $40.3M cash reserves and 3.61x current ratio provides 2-3 year operational runway
- Minimal debt burden (0.03x D/E ratio) reduces financial distress risk and refinancing concerns
HOOK Investment Risks to Consider
- Severe cash burn with $15.4M net loss against $2.0M revenue creates unsustainable operating model
- Operating margin of -891.9% reveals inability to generate positive returns from core operations at any scale
- Pharma development dependency creates binary outcomes; failure of pipeline candidates could render company insolvent despite cash reserves
Key Metrics to Watch
- Quarterly cash burn rate and estimated months of runway
- Clinical trial progression and regulatory milestone achievements
- Operating cash flow inflection point and path to positive unit economics
HOOK Financial Metrics
💡 AI Analyst Insight
The relatively thin 1.6% FCF margin may limit capital allocation flexibility. Strong liquidity with a 3.61x current ratio provides a solid financial cushion.
HOOK Profitability Ratios
HOOK vs Healthcare Sector
How HOOKIPA Pharma Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HOOK Overvalued or Undervalued?
Based on fundamental analysis, HOOKIPA Pharma Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HOOK Balance Sheet & Liquidity
HOOK 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: HOOKIPA Pharma Inc.'s revenue has grown significantly by 124% over the 5-year period, indicating strong business expansion. The most recent EPS of $-9.91 indicates the company is currently unprofitable.
HOOK Growth Metrics (YoY)
HOOK Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $2.0M | $14.4M | $1.14 |
| Q3 2024 | $4.7M | -$13.8M | $-1.10 |
| Q2 2024 | $1.3M | -$4.7M | $-0.38 |
| Q1 2024 | $3.2M | $14.4M | $0.11 |
| Q3 2023 | $2.2M | -$16.4M | $-0.17 |
| Q2 2023 | $2.7M | -$16.4M | $-0.22 |
| Q1 2023 | $1.4M | -$18.0M | $-0.27 |
| Q3 2022 | $2.2M | -$16.4M | $-0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HOOK Capital Allocation
HOOK SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for HOOKIPA Pharma Inc. (CIK: 0001760542)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HOOK
What is the AI rating for HOOK?
HOOKIPA Pharma Inc. (HOOK) has an AI rating of SELL with 45% confidence, based on fundamental analysis of SEC EDGAR filings.
What are HOOK's key strengths?
Claude: Revenue growth of 118.3% YoY demonstrates market traction and adoption. Strong liquidity position with $40.3M cash reserves and 3.61x current ratio provides 2-3 year operational runway.
What are the risks of investing in HOOK?
Claude: Severe cash burn with $15.4M net loss against $2.0M revenue creates unsustainable operating model. Operating margin of -891.9% reveals inability to generate positive returns from core operations at any scale.
What is HOOK's revenue and growth?
HOOKIPA Pharma Inc. reported revenue of $2.0M.
Does HOOK pay dividends?
HOOKIPA Pharma Inc. does not currently pay dividends.
Where can I find HOOK SEC filings?
Official SEC filings for HOOKIPA Pharma Inc. (CIK: 0001760542) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HOOK's EPS?
HOOKIPA Pharma Inc. has a diluted EPS of $-1.23.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HOOK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, HOOKIPA Pharma Inc. has a SELL rating with 45% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HOOK stock overvalued or undervalued?
Valuation metrics for HOOK: ROE of -45.3% (sector avg: 15%), net margin of -769.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HOOK stock in 2026?
Our dual AI analysis gives HOOKIPA Pharma Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HOOK's free cash flow?
HOOKIPA Pharma Inc.'s operating cash flow is $52.0K, with capital expenditures of $20.0K. FCF margin is 1.6%.
How does HOOK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -769.8% (avg: 12%), ROE -45.3% (avg: 15%), current ratio 3.61 (avg: 2).